

# **SUPPLEMENTAL MATERIAL**

## Data S1.

### Additional details on statistical analysis

Analysis was based on a long-formatted database, as the sample below:

ID	Order	Product	Timing	Measurement
1	1	A	Baseline	Y1
1	2	A	Post	Y2
1	3	B	Baseline	Y3
1	4	B	Post	Y4
1	5	C	Baseline	Y5
1	6	C	Post	Y6
2	1	B	Baseline	Y7
2	2	B	Post	Y8
2	3	C	Baseline	Y9
2	4	C	Post	Y10
2	5	A	Baseline	Y11
2	6	A	Post	Y12
...	...	...	...	...

The model for the within-product before-after analysis was:

$$Y_{ij} = \beta_0 + \beta_1 \text{Time} + u_1 \text{ID} + u_2 \text{Order} + \varepsilon$$

with  $\beta$  representing the fixed effects,  $u$  the random effects, and  $\varepsilon$  the Gaussian error term.

The Stata code for the within-product before-after analysis was:

```
mixed Measurement Timing || ID:, || Order:, covariance(identity)
```

Conversely, the model for the between-product interaction analysis was:

$$Y_{ij} = \beta_0 + \beta_1 \text{Time} + \beta_2 \text{Product} + \beta_3 \text{Time} * \text{Product} + u_1 \text{ID} + u_2 \text{Order} + \varepsilon$$

with  $\beta$  representing the fixed effects,  $u$  the random effects, and  $\varepsilon$  the Gaussian error term.

Accordingly, the Stata code for the between-product interaction analysis was:

```
mixed Measurement Timing##Product || ID:, || Order:, covariance(identity)
```

A sample screenshot for the Stata output is the following:

```
. mixed FMD Pre0Post1##TC1EC2HNS3 || ID:, || Order:, covariance(identity)
```

Performing EM optimization:

Performing gradient-based optimization:

```
Iteration 0: log likelihood = -248.25534
Iteration 1: log likelihood = -246.75537
Iteration 2: log likelihood = -246.71072
Iteration 3: log likelihood = -246.71072
```

Computing standard errors:

```
Mixed-effects ML regression          Number of obs    =    115
```

Group Variable	No. of Groups	Observations per Group		
		Minimum	Average	Maximum
ID	20	3	5.8	6
Order	58	1	2.0	2

```
Log likelihood = -246.71072          Wald chi2(5)      =    91.50
                                     Prob > chi2       =    0.0000
```

FMD	Coef.	Std. Err.	z	P> z	[95% Conf. Interval]	
1.Pre0Post1	-3.8114	.5404618	-7.05	0.000	-4.870685	-2.752114
TC1EC2HNS3						
2	-.0707635	.5545494	-0.13	0.898	-1.15766	1.016133
3	-.1178998	.5404618	-0.22	0.827	-1.177185	.9413859
Pre0Post1#TC1EC2HNS3						
1 2	1.389178	.7785131	1.78	0.074	-.1366801	2.915035
1 3	1.5004	.7580794	1.98	0.048	.0145915	2.986208
_cons	6.2149	.6280043	9.90	0.000	4.984034	7.445766

Random-effects Parameters	Estimate	Std. Err.	[95% Conf. Interval]	
ID: Identity				
var(_cons)	4.871662	1.691218	2.467056	9.620007
Order: Identity				
var(_cons)	1.25e-17	6.91e-17	2.56e-22	6.14e-13
var(Residual)	2.825853	.4095205	2.127131	3.754094

```
LR test vs. linear regression:      chi2(2) =    70.26  Prob > chi2 = 0.0000
```


Note: LR test is conservative and provided only for reference.

**Table S1. Additional inferential analysis.**


Feature	Point estimate of effect (95% confidence interval)		
	EVC vs TC	EVC vs HNBC	TC vs HNBC
Primary endpoints			
Soluble Nox2-derived peptide (pg/mL)	-4.30 (-12.74; 4.14)	<b>-9.55 (-16.00; -3.10)</b>	<b>-13.85 (-22.29; -5.41)</b>
Flow-mediated dilation (%)	1.39 (-0.14; 2.92)	0.11 (-1.25; 1.47)	<b>1.50 (0.02; 2.97)</b>
Additional endpoints			
Nitric oxide bioavailability (μM)	5.18 (-4.77; 15.13)	3.35 (-5.73; 12.42)	8.52 (-1.42; 18.48)
H <sub>2</sub> O <sub>2</sub> production (μmol/L)	-4.58 (-9.89; 0.74)	-0.94 (-3.81; 1.94)	<b>-5.51 (-10.83; -0.20)</b>
H <sub>2</sub> O <sub>2</sub> breakdown activity (%)	<b>11.63 (0.64; 22.61)</b>	8.76 (-1.40; 18.91)	<b>20.38 (9.40; 31.37)</b>
8-iso-prostaglandin F-2α-III (pmol/L)	<b>-44.4 (-66.1; -22.7)</b>	<b>-31.0 (-52.2; -9.8)</b>	<b>-75.4 (-97.1; -53.7)</b>
Vitamin E (μmol/mmol)	<b>1.09 (0.03; 2.15)</b>	<b>1.25 (0.22; 2.29)</b>	-0.16 (-1.22; 0.90)
Soluble CD40 ligand (ng/mL)	<b>-1.38 (-2.74; -0.02)</b>	0.13 (-1.21; 1.47)	-1.25 (-2.61; 0.11)
Soluble P-selectin (ng/ml)	<b>-3.30 (-4.92; -1.68)</b>	-0.13 (-1.21; 0.96)	<b>-3.43 (-5.04; -1.81)</b>
Systolic blood pressure (mm Hg)	-2.05 (-4.64; 0.54)	-1.95 (-4.42; 0.52)	<b>-4.00 (-6.59; -1.41)</b>
Diastolic blood pressure (mm Hg)	-1.00 (-4.14; 2.24)	-2.20 (-4.87; 0.47)	<b>-3.20 (-6.34; -0.06)</b>
Mean blood pressure (mm Hg)	-1.35 (-3.93; 1.23)	-2.12 (-4.26; 0.03)	<b>-3.47 (-6.05; -0.88)</b>
Cotinine (ng/mL)	1.70 (-10.32; 13.72)	-2.20 (-14.31; 9.91)	-0.50 (-12.52; 11.52)

EVC=electronic vaping cigarette; H<sub>2</sub>O<sub>2</sub>=hydrogen peroxide; HNBC=heat-not-burn cigarette; TC=traditional tobacco cigarette


**Figure S1. Consolidated Standards of Reporting Trials (CONSORT) subject flow diagram (left panel), and measurement protocol (right panel).** BP=blood pressure; EVC=electronic vapng cigarette; FMD=flow-mediated dilation; HNBC=heat-not-burn cigarette; TC=traditional tobacco cigarette.



**Figure S2. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) production.** Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.




**Figure S3. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on 8-iso-prostaglandin F-2 $\alpha$ -III (8-iso-PGF2a).** Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.




**Figure S4. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on vitamin E.**

Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.







**Figure S5. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) breakdown activity (HBA). Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.**




**Figure S6. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on soluble CD40 ligand.** Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.




**Figure S7. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on soluble P-selectin.** Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.




**Figure S8. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on systolic blood pressure (SBP). Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.**




**Figure S9. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on diastolic blood pressure (DBP). Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.**




**Figure S10. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on mean blood pressure (MBP). Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.**



**Figure S11. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on nitric oxide (NO) bioavailability.** Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.




**Figure S12. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on smoking satisfaction, appraised with the explicit question “Was the cigarette enjoyable?”, and answers scored using a subjective scale from 0 (no effect) to 100 (maximum effect). Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.**





**Figure S13. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on smoking satisfaction, appraised with the explicit question “Was the cigarette satisfying?”, and answers scored using a subjective scale from 0 (no effect) to 100 (maximum effect). Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.**



**Figure S14. Impact of using electronic vaping cigarette (EVC), traditional tobacco cigarette (TC), and heat-not-burn cigarette (HNBC) on smoking satisfaction, appraised with the explicit question “Soon after smoking did your desire for another cigarette decrease?”, and answers scored using a subjective scale from 0 (no effect) to 100 (maximum effect). Boxplots represent median, 1<sup>st</sup> quartile, 3<sup>rd</sup> quartile, 5<sup>th</sup> percentile, 95<sup>th</sup> percentile, and outliers.**

